Allogene Therapeutics (ALLO) Net Income towards Common Stockholders (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Net Income towards Common Stockholders data on file, last reported at -$145.2 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 96.88% year-over-year to -$145.2 million; the trailing twelve-month figure through Mar 2026 stood at -$325.8 million (up 18.94% YoY), and the FY2025 full-year result was -$190.9 million, up 25.9% from the prior year.
• Net Income towards Common Stockholders slipped to -$145.2 million in Q1 2026, from -$39.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$39.1 million in Q4 2025 to a low of -$224.9 million in Q3 2022.
• A 5-year average of -$99.9 million and a median of -$81.5 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 1436157.14% in 2022 and jumped 60.27% in 2025, its largest moves.
• Tracing ALLO's Net Income towards Common Stockholders over 5 years: stood at -$100.5 million in 2022, then climbed by 27.55% to -$72.8 million in 2023, then advanced by 21.0% to -$57.5 million in 2024, then jumped by 32.13% to -$39.1 million in 2025, then sank by 271.79% to -$145.2 million in 2026.
• Business Quant data shows ALLO's Net Income towards Common Stockholders at -$145.2 million in Q1 2026, -$39.1 million in Q4 2025, and -$65.3 million in Q3 2025.